Similar articles

• B-lymphoma cells escape rituximab-triggered elimination by NK cells through increased HLA class I expression.

  Borgerding A, Hasenkamp J, Engelke M, Burkhart N, Trümper L, Wienands J, Glass B. Borgerding A, et al. Exp Hematol. 2010 Mar;38(3):213-21. doi: 10.1016/j.exphem.2009.12.007. Epub 2010 Jan 6. Exp Hematol. 2010. PMID: 20056126
• KIR downregulation by IL-12/15/18 unleashes human NK cells from KIR/HLA-I inhibition and enhances killing of tumor cells.

  Ewen EM, Pahl JHW, Miller M, Watzl C, Cerwenka A. Ewen EM, et al. Eur J Immunol. 2018 Feb;48(2):355-365. doi: 10.1002/eji.201747128. Epub 2017 Nov 29. Eur J Immunol. 2018. PMID: 29105756
• KIR/HLA interactions negatively affect rituximab- but not GA101 (obinutuzumab)-induced antibody-dependent cellular cytotoxicity.

  Terszowski G, Klein C, Stern M. Terszowski G, et al. J Immunol. 2014 Jun 15;192(12):5618-24. doi: 10.4049/jimmunol.1400288. Epub 2014 May 2. J Immunol. 2014. PMID: 24795454 Clinical Trial.
• High-Risk Leukemia: Past, Present, and Future Role of NK Cells.

  Mavers M, Bertaina A. Mavers M, et al. J Immunol Res. 2018 Apr 15;2018:1586905. doi: 10.1155/2018/1586905. eCollection 2018. J Immunol Res. 2018. PMID: 29850617 Free PMC article. Review.
• How important is NK alloreactivity and KIR in allogeneic transplantation?

  Shaffer BC, Hsu KC. Shaffer BC, et al. Best Pract Res Clin Haematol. 2016 Dec;29(4):351-358. doi: 10.1016/j.beha.2016.10.010. Epub 2016 Oct 20. Best Pract Res Clin Haematol. 2016. PMID: 27890259 Free PMC article. Review.